GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Gross Margin %

Glenmark Pharmaceuticals (NSE:GLENMARK) Gross Margin % : 58.04% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Glenmark Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was ₹14,280 Mil. Glenmark Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was ₹24,603 Mil. Therefore, Glenmark Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 58.04%.


The historical rank and industry rank for Glenmark Pharmaceuticals's Gross Margin % or its related term are showing as below:

NSE:GLENMARK' s Gross Margin % Range Over the Past 10 Years
Min: 60.33   Med: 62.42   Max: 67.36
Current: 60.33


During the past 13 years, the highest Gross Margin % of Glenmark Pharmaceuticals was 67.36%. The lowest was 60.33%. And the median was 62.42%.

NSE:GLENMARK's Gross Margin % is ranked better than
73.54% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.705 vs NSE:GLENMARK: 60.33

Glenmark Pharmaceuticals had a gross margin of 58.04% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Glenmark Pharmaceuticals was 0.00% per year.


Glenmark Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Glenmark Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Gross Margin % Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.22 61.19 63.01 60.75 61.63

Glenmark Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.18 58.10 63.19 62.10 58.04

Competitive Comparison of Glenmark Pharmaceuticals's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Gross Margin % falls into.



Glenmark Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Glenmark Pharmaceuticals's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=78421.5 / 127254.33
=(Revenue - Cost of Goods Sold) / Revenue
=(127254.33 - 48832.8) / 127254.33
=61.63 %

Glenmark Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=14280.3 / 24602.9
=(Revenue - Cost of Goods Sold) / Revenue
=(24602.9 - 10322.58) / 24602.9
=58.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Glenmark Pharmaceuticals  (NSE:GLENMARK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Glenmark Pharmaceuticals had a gross margin of 58.04% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Glenmark Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines